Peter Kleinhenz

Biography

 Peter Kleinhenz has been actively involved in technology-based businesses as an entrepreneur, consultant, or professional investor for over 28 years and in the life sciences sector for over 25 years. His experience in life science includes investments in: devices, diagnostics, biologics, and healthcare services. He joined Fletcher Spaght Ventures as a Venture Partner in 2009. He represents Fletcher Spaght as a board member at Swift Biosciences and was a board member or advisor at Surgiquest, Inc. (acquired by Con Med, Inc.) and Cayenne Medical Inc.(acquired by Zimmer Biomet). From 2001 to 2016 as a Managing Director, Peter represented CID Capital, Inc. as a board member or adviser in the following investments: AxioMed Spine Corporation, MedVantx, Inc., RedPath Integrated Pathology, Inc. (acquired by PDI, Inc.), EKOS Corporation (acquired by BTG International, Inc.), Renal Solutions (acquired by Fresenius Medical Care), QIS Solutions (acquired by ABeam Consulting), and Waterlink, Inc. Prior to joining CID Capital in 2001, Peter served as Vice President of Commercialization-Life Sciences for Battelle Memorial Institute working in their medical device, pharmaceutical, and toxicology sectors. He was CEO and principal owner of Progenics Inc., a product development and pilot manufacturing company for medical products and industrial controls. He was part of the founding business team of Neoprobe Corporation, a biologic product and medical device company focused on cancer detection and therapy. Peter received an MBA from Case Western Reserve University, a bachelor’s degree from Loyola University of Chicago, and is a Certified Public Accountant (inactive status) in Ohio.

Research Interest

 Medicine,Therapeutics,Biology